Today: 2 March 2026
Subscribe
Browse Category

Mergers & Acquisitions 12 November 2025 - 18 November 2025

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Pfizer launched a U.S. dollar bond sale aiming to raise at least $5 billion to help fund its recent Metsera acquisition, which closed Nov. 13 for up to $10 billion. The offering may include up to seven tranches, with early talks on a 40-year note at about 125 basis points over Treasuries. Pfizer shares traded near $25.11 as of 16:12 UTC, little changed on the day.
18 November 2025
·····
Blue Owl’s BDC Shake‑Up (Nov. 17, 2025): OBDC–OBDC II Merger Puts ~20% Haircut on the Table for Retail Holders—But Double‑Digit Yields Lure Value Buyers

Blue Owl’s BDC Shake‑Up (Nov. 17, 2025): OBDC–OBDC II Merger Puts ~20% Haircut on the Table for Retail Holders—But Double‑Digit Yields Lure Value Buyers

Blue Owl Capital will merge its private OBDC II into the public Blue Owl Capital Corporation (NYSE: OBDC) in an all-stock deal expected to close Q1 2026. OBDC II investors face an implied 20% value loss, as OBDC shares trade at an $11.89 price versus a $14.89 NAV. Both boards approved the deal; OBDC II holders must still vote. Fitch placed OBDC II on Rating Watch Positive after the announcement.
17 November 2025
·
Clearwater Analytics (CWAN) Soars on Warburg Pincus & Permira Buyout Buzz — Key Updates for November 17, 2025

Clearwater Analytics (CWAN) Soars on Warburg Pincus & Permira Buyout Buzz — Key Updates for November 17, 2025

Clearwater Analytics shares surged as much as 14% in pre-market trading Monday after reports that Warburg Pincus and Permira are in talks to acquire the company. The stock traded near $21.89 before the open, later settling up about 3.9% by late morning. No formal agreement has been announced. Clearwater, Warburg, and Permira declined to comment.
17 November 2025
·
E.W. Scripps (SSP) Soars as Sinclair Builds 8.2% Stake and Pushes for Takeover on November 17, 2025

E.W. Scripps (SSP) Soars as Sinclair Builds 8.2% Stake and Pushes for Takeover on November 17, 2025

Sinclair Inc. revealed an 8.2% stake in The E.W. Scripps Company on Nov. 17, 2025, and confirmed ongoing merger talks, pushing SSP shares up over 20%. Scripps’ board said it will protect shareholders and stick to its strategic plan. Sinclair claims the deal would bring $300 million in annual cost synergies without external financing. The proposed merger would combine more than 230 local TV stations.
17 November 2025
···
Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics shares jumped nearly 30% and traded around $2 after last week’s $78 million takeover deal with XenoTherapeutics. The offer includes about $1.82 per share in cash plus a non-transferable contingent value right tied to future asset sales and milestones. The transaction is expected to close in Q1 2026, pending shareholder and court approval in Québec.
17 November 2025
·
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer completed its $10 billion acquisition of Metsera on November 13, 2025, making Metsera a wholly owned subsidiary and delisting its shares from Nasdaq. Metsera stock last traded at about $70.50 per share before removal. S&P and FTSE Russell are dropping MTSR from their indices. Antitrust scholars are citing Novo Nordisk’s failed bid as a case study in attempted monopolization.
17 November 2025
···
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson will acquire Halda Therapeutics for $3.05 billion in cash, expanding its oncology portfolio. Halda’s lead drug candidate targets advanced prostate cancer. The deal is expected to close in the coming months, pending regulatory approval. J&J faces declining Stelara sales as biosimilar competition increases.
17 November 2025
··
TotalEnergies seals €5.1bn all‑stock JV for 50% of EPH’s flexible power portfolio, adding 14GW across Europe (17 Nov 2025)

TotalEnergies seals €5.1bn all‑stock JV for 50% of EPH’s flexible power portfolio, adding 14GW across Europe (17 Nov 2025)

TotalEnergies will acquire a 50% stake in EPH’s flexible power generation platform for €5.1 billion in stock, forming a joint venture with over 14 GW of assets across Western Europe. EPH will receive 95.4 million new TotalEnergies shares, gaining about 4.1% of the company. The deal values the portfolio at €10.6 billion and is expected to close by mid-2026, pending approvals.
17 November 2025
····
WPP Share Price Today: London Stock Jumps on Takeover Talk as FTSE 100 Exit Looms (17 November 2025)

WPP Share Price Today: London Stock Jumps on Takeover Talk as FTSE 100 Exit Looms (17 November 2025)

WPP shares closed up 3.4% at 298p in London on Monday after renewed takeover speculation involving Havas, Apollo, and KKR. The stock traded as high as 307.5p intraday, with about 2.7 million shares changing hands. Despite the rebound, WPP’s share price remains down 64% over the past year, near levels last seen in the late 1990s.
17 November 2025
···
Warner Bros Discovery Stock Skyrockets on $60B Takeover Rumors

Warner Bros. Discovery (WBD) Stock Climbs as Paramount, Comcast and Netflix Line Up Bids in High‑Stakes Auction – November 14, 2025

Warner Bros. Discovery shares jumped as Paramount Skydance, Comcast, and Netflix prepared formal bids for all or parts of the company, sending the stock near a 52-week high around $23. Lawmakers raised antitrust concerns over a potential Netflix deal, while WBD revised CEO David Zaslav’s contract to address possible sale scenarios. First-round bids are due November 20. WBD’s market cap neared $55 billion.
14 November 2025
·····
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Merck said it will acquire Cidara Therapeutics for $221.50 per share in cash, valuing the deal at about $9.2 billion. The offer represents a 109% premium to Cidara’s last closing price and sent CDTX shares up more than 100%. Both companies’ boards approved the deal, which is expected to close in early 2026 pending regulatory clearance. Merck aims to secure Cidara’s lead flu-prevention drug, CD388.
14 November 2025
··
Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor shares rose 1.5% to about $15.00 midday Friday after Mizuho upgraded the stock to “Neutral” and raised its price target to $17.00, citing an $85 million cost-cutting plan and a pivot toward its Experiences business. The move follows a 6.75% drop Thursday and comes amid layoffs, a planned Viator merger, and preparations to launch an AI-powered travel product.
14 November 2025
···
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck will acquire Cidara Therapeutics for about $9.2 billion, paying $221.50 per share in cash—a 109% premium to Cidara’s last close. The deal gives Merck rights to CD388, a Phase 3 long-acting flu prevention drug. Cidara shares doubled in pre-market trading. The transaction is expected to close in Q1 2026, pending approvals.
14 November 2025
···
Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Mersana Therapeutics (MRSN) Soars on Up to $285 Million Day One Biopharmaceuticals Buyout: All the Key News on November 13, 2025

Day One Biopharmaceuticals will acquire Mersana Therapeutics in a deal valued at up to $285 million, offering $25 per share in cash plus contingent value rights up to $30.25 per share. Mersana’s board and major holders support the agreement. MRSN shares jumped as much as 200% pre-market. Halper Sadeh LLC launched a shareholder fairness investigation.
13 November 2025
···
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Today, November 13, 2025: BioNTech Stake Sale, Metsera Deal and a 6%+ Dividend Put PFE Back in Focus

Pfizer shares rose 1.4% to $25.87 Thursday after the company moved to sell its remaining 4.55 million BioNTech ADRs, potentially raising over $500 million. The stock traded between $25.26 and $25.95, with a market cap near $147 billion and a forward dividend yield of about 6.6–7%. BioNTech shares fell on the news. Investors also weighed Pfizer’s recent $10 billion Metsera deal.
13 November 2025
···
BP Stock Soars as Oil Rally and Strategic Shift Boost Investor Confidence

BP Nears Castrol Sale: Stonepeak in Advanced Talks as Valuation Swirls Around $8 Billion (Nov 13, 2025)

BP is in advanced talks to sell its Castrol lubricants business to Stonepeak, with negotiations ongoing and no deal guaranteed, according to Reuters and Offshore Engineer. Bids were submitted in September, and market estimates value Castrol near $8 billion. BP aims to raise $20 billion from divestments by 2027 amid pressure from activist investor Elliott. BP and Stonepeak have not commented.
13 November 2025
···
CMCT Stock Soars After $44M Sale of Lending Arm; CFO Transition and SBA Consent in Focus (Nov. 12, 2025)

CMCT Stock Soars After $44M Sale of Lending Arm; CFO Transition and SBA Consent in Focus (Nov. 12, 2025)

Creative Media & Community Trust Corporation agreed to sell its lending division, First Western SBLC/PMC Commercial Trust, to Peachtree Group affiliate PG FR Holding for about $44 million. The deal is expected to net CMCT $31 million after debt and costs, pending SBA approval. CMCT shares surged 66% intraday following the announcement. CFO Barry N. Berlin will resign at closing and is expected to join the buyer.
12 November 2025
·
1 … 12 13 14 15 16 … 20
Go toTop